APTEVO THERAPEUTICS INC (APVO) Stock News

NASDAQ:APVO - Nasdaq - US03835L4059 - Common Stock - Currency: USD

1.96 -0.03 (-1.51%)

After market: 2.03 +0.07 (+3.57%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

APVO Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: ACCESS Newswire

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

10 days ago - By: The Motley Fool

Aptevo Reports 85% Remission in Q2

10 days ago - By: ACCESS Newswire

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

13 days ago - By: ACCESS Newswire - Mentions: SXTP

Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

a month ago - By: Yahoo Finance

Aptevo Meets Nasdaq $2.5M Equity Requirement

2 months ago - By: ACCESS Newswire

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

2 months ago - By: ACCESS Newswire

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

3 months ago - By: ACCESS Newswire

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

2 months ago - By: Benzinga - Mentions: HUSA JBLU MCD URA ...

Benzinga Bulls And Bears: Circle, Sunrun, JetBlue — And Mideast Has Markets Nervous

2 months ago - By: Benzinga - Mentions: MBRX RGC GALT LUCY ...

12 Health Care Stocks Moving In Friday's Intraday Session

2 months ago - By: ACCESS Newswire

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

2 months ago - By: ACCESS Newswire

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

2 months ago - By: ACCESS Newswire

Aptevo Participating in the BIO International Convention

3 months ago - By: ACCESS Newswire

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

3 months ago - By: ACCESS Newswire

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

4 months ago - By: ACCESS Newswire

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

4 months ago - By: ACCESS Newswire

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules